Vaccination schedule. Vaccination schedule. Vaccinations were given in cycles; each cycle consisted of four injections (vertical lines). Up to four additional.

Slides:

Advertisements

Similar presentations

Synergistic antitumor effect of anti-CD40/CpG and 14

Advertisements

Volume 143, Issue 2, Pages (February 2013)

Volume 17, Issue 9, Pages (September 2009)

Immunologic effects of F16-IL2 therapy.

Overview of next-generation sequencing, neoantigen prediction, and functional T-cell analyses. Overview of next-generation sequencing, neoantigen prediction,

Clinical response to F16-IL2 and LDAC in patients with AML bone marrow involvement. Clinical response to F16-IL2 and LDAC in patients with AML bone marrow.

Figure 2 Peptide vaccination using TAA-derived long peptides

Interleukin (IL)-1β-producing cells in peripheral blood mononuclear cells (PBMCs). Interleukin (IL)-1β-producing cells in peripheral blood mononuclear.

Immunologic Characterization of HIV-Specific DNA Vaccine

Role of the T-cell interferon-gamma release assays in preventing reactivation of latent tuberculosis infection in immunosuppressed patients in treatment.

Peripheral blood lymphocytes genetically modified to express the self/tumor antigen MAGE-A3 induce antitumor immune responses in cancer patients by Raffaella.

Type 17 immunity is increased in STAT1−/− mice.

H-H. Lin, K-L. Hsu, W. W-C. Ko, Y-C. Yang, Y-W. Chang, M-C. Yu, K-T

Induction of Graft-versus-Leukemia (GVL) Effect without Graft-versus-Host Disease (GVHD) by Pretransplant Donor Treatment with Immunomodulators Shoshana.

Pilot Study of 1650-G: A Simplified Cellular Vaccine for Lung Cancer

Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before.

Viral load and CD4+ T cells in CD8+ T cell–depleted YU-2–infected MISTRG mice. Viral load and CD4+ T cells in CD8+ T cell–depleted YU-2–infected MISTRG.

The PI3K–Akt pathway is essential for the in vivo maintenance of murine Tregs. The PI3K–Akt pathway is essential for the in vivo maintenance of murine.

Treatment of human MCC tumors with intralesional IFNβ is associated with MHC-I upregulation. Treatment of human MCC tumors with intralesional IFNβ is associated.

Fig. 4 Expression of cleaved caspase 3, PD-L1, and PD-1 in HGGs after reovirus treatment. Expression of cleaved caspase 3, PD-L1, and PD-1 in HGGs after.

Course of disease and immune responses seen in patient LAU 672.

Volume 25, Issue 6, Pages (June 2017)

Figure 2 Logistical requirements for autologous

Volume 18, Issue 3, Pages (March 2003)

Stanford L Peng, Andrea J Gerth, Ann M Ranger, Laurie H Glimcher

Volume 25, Issue 6, Pages (June 2017)

Exosomes from M1-Polarized Macrophages Potentiate the Cancer Vaccine by Creating a Pro-inflammatory Microenvironment in the Lymph Node Lifang Cheng,

Adaptive immune responses and NK activity.

Volume 18, Issue 9, Pages (September 2010)

Accuracy of an immune diagnostic assay based on RD1 selected epitopes for active tuberculosis in a clinical setting: a pilot study D. Goletti, S. Carrara,

Volume 8, Issue 2, Pages (August 2003)

Fig. 5 Treatment with an OX40 agonist antibody of 3-week-old HBVtgRag−/− mice or mice with chronic HBV disease results in an altered immune response to.

Epicutaneous Application of CpG Oligodeoxynucleotides with Peptide or Protein Antigen Promotes the Generation of CTL Sandra K. Klimuk, Hossain M. Najar,

Molecular Therapy - Oncolytics

CCR4 antagonists amplify immunogenicity of vaccines in vivo.

Ag 85A–specific immune responses.

Figure 1 Peripheral blood lymphocyte counts during dose titrationB-lymphocyte (CD19+; A) and total lymphocyte (CD45+; B) counts (cells/µL) in peripheral.

B cell development in wild-type and Syk-AQL mice.

Figure 2 Effect of Dex on cytokine production by MIF−/− or Wt T cells in EAE Wild-type (Wt) and macrophage migration inhibitory factor (MIF)−/− mice were.

Immune cell populations associated with type I IFNGS test status and disease activity. Immune cell populations associated with type I IFNGS test status.

Fig. 2 In situ vaccination of CpG in combination with anti-OX40 antibody cures established local and distant tumors. In situ vaccination of CpG in combination.

BMS blocks functional responses in primary immune cells driven by IFNα

Specific recognition of HOM-MEL-40/SSX2-derived p pulsed targets by p stimulated T-cells from patients with HOM-MEL-40/SSX2 positive breast.

Natural processing and presentation of the HOM-MEL-40/SSX2-derived p peptide. Natural processing and presentation of the HOM-MEL-40/SSX2-derived.

Combined BRAFi and anti-CTLA4 administration leads to prolonged antitumor immunity in a patient with metastatic melanoma. Combined BRAFi and anti-CTLA4.

Specificity of HOM-MEL-40/SSX2 p stimulated CD8+ T-cells.

Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model in vivo. Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model.

A2/Melan-A multimer+ CD8+ allorestricted CTL clones derived from donor DR fail to significantly recognize DR self-targets. A2/Melan-A multimer+ CD8+ allorestricted.

Positive correlations between disease course and treatment-induced immune responses. Positive correlations between disease course and treatment-induced.

Functional characterization of polyclonal Melan-A monospecific allorestricted CTLs. (A) Recognition of Melan-A peptides by the polyclonal Melan-A monospecific.

Immune responses to 12MP and 6MHP.

HLA-A*0201 restriction of SSX2-derived p stimulated CD8+ T-cells.

Increase in proliferation and activation of immune cells in peripheral blood after NKTR-214 treatment. Increase in proliferation and activation of immune.

Cytotoxic activity of CD8+ T-cells stimulated with SSX2-derived p

Uptake of TEX by DCs in vivo.

Immunologic and pharmacokinetic studies.

Effect of nivolumab or ipilimumab on immune responses to vaccination in cynomolgus monkeys. Effect of nivolumab or ipilimumab on immune responses to vaccination.

Deletion of Tgfbr2 in myeloid cells elevated IFN-γ production in CD8+ T cells, and systemic IFN-γ neutralization diminished metastasis inhibition in Tgfbr2MyeKO.

Fig. 4 S. elongatus therapy does not elicit a pathologic immune response nor persist in tissue long-term. S. elongatus therapy does not elicit a pathologic.

Intratumoral changes in critical lymphocyte populations and numbers after NKTR-214 treatment. Intratumoral changes in critical lymphocyte populations and.

Increased accumulation of pmel-1 T cells to tumor sites and enhanced antitumor immune response in mice receiving ACT combined with anti-PD-1 antibody treatment.

Serum IFNγ and immune responses following tecemotide/cisplatin combination treatment in a urethane-induced hMUC1.Tg lung cancer mouse model. Serum IFNγ.

Anti–TGF-β1 antibody neutralizes APB-mediated immune suppression.

Immunofluorescence (A-C) and IHC (D-G) analysis of XAGE-1b.

Moderate-affinity vaccine antigens elicited greatest antitumor response. Moderate-affinity vaccine antigens elicited greatest antitumor response. Wild-type.

Antigen-specific cytokine-producing cells (IFN-γ and IL-5) detected by ELISPOT assay 3 weeks after the 3rd immunization. Antigen-specific cytokine-producing.

Induction of NY-ESO-1-specific CD4+ and CD8+ T cell responses after in vitro presensitization with NY-ESO-1 p or Ad2/ESO. Induction of NY-ESO-1-specific.

MDSC population in patient peripheral blood.

Waterfall plots in 82 ipilimumab-refractory patients receiving nivolumab (3 mg/kg) with (n = 14) or without (n = 82) a peptide vaccine. Waterfall plots.

Design and operation of p.DOM-epitope vaccines.

Presentation transcript:

Vaccination schedule. Vaccination schedule. Vaccinations were given in cycles; each cycle consisted of four injections (vertical lines). Up to four additional and similar cycles (continued vaccination, not shown) were given to patients without major disease progression, with 2-mo intervals between cycles. Vaccines contained 100 µg each of Melan-A and influenza peptides injected as mixtures in saline or together with 660 µl AS02B or 600 µl IFA. Before starting treatment and 2 wk after the last vaccine of each cycle, peripheral blood cells (PBLs) were withdrawn (vertical arrows) for lymphocyte analyses by flow cytometry and IFN-gamma ELISPOT assays. The patients in treatment group IIIb were on a different schedule (not shown) since vaccines were given biweekly and PBLs were obtained 1 wk after the last vaccine of each cycle. Danielle Liénard et al. Cancer Immun 2004;4:4 Copyright © 2004 by Daniel E. Speiser